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as well as cancer and cardiovascular disease. Although Akt signalling has been identiﬁed as a promising
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compartments, and have unique modes of activation. Consistent with in vitro ﬁndings, genetic studies in mice
show distinct effects of individual Akt isoforms on the pathophysiology of cardiovascular disease. This review
summarises recent studies of individual Akt isoforms in atherosclerosis, vascular remodelling and aneurysm
formation, to provide a comprehensive overview of Akt function in vascular disease.
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Identiﬁed in 1991 [1,2], the serine/threonine protein kinase Akt
(Protein Kinase B, PKB) has emerged as a key mediator of cell prolif-
eration, migration, apoptosis, angiogenesis and metabolism [3–6],
acting downstream of the insulin-like growth factor 1 (IGF1)/phos-
phatidylinositol 3-kinase (PI3K) signal transduction pathways.
Akt kinases comprise three mammalian isoforms (Akt1, Akt2 and
Akt3 or PKBα/β/γ), which are similar in structure but distinct in function.
All Akt isoforms contain an N-terminal regulatory pleckstrin homology
(PH) domain, a central kinase domainwith serine/threonine speciﬁcity,
and a C-terminal hydrophobic domain [1,7,8]. Studies over the last
decade using various transgenic and knockout mice have shown that
Akt isoforms have partly redundant but also distinct functions in
physiological and pathological processes, in part due to different
tissue-speciﬁc expression of Akt isoforms. For example, while Akt1 is
ubiquitously expressed, Akt2 is highly expressed in insulin-responsive
tissues such as adipose tissue, liver and skeletal muscle, and Akt3 is
highly expressed in the brain [9–11]. Mice lacking Akt1 are viable but
have signiﬁcant neonatal mortality and are smaller in size than
littermate controls. Akt1-null cells display higher rates of apoptosis,
indicating a critical role for Akt1 in cell survival [12,13]. Total body
Akt2 knockout mice develop severe type-2 diabetes [13], and cells
deﬁcient in Akt2 have impaired glucose utilisation [14]. Akt3-deﬁcient
mice display no growth retardation but a 20% smaller brain size,
suggesting that Akt3 is important for postnatal brain development
[15]. Double knockout mice of Akt isoforms have been generated to
assess overlapping roles in homeostasis and development. Mice
deﬁcient in Akt1/2 die shortly after birth [15], and Akt1/3 double
knockout mice are embryonic lethal [15]. In contrast, Akt2/3 double
knockout mice are viable but display impaired glucose homeostasis
and growth retardation [9], whereas Akt1+/−/Akt2−/−/Akt3−/− mice
are viable. This indicates that a single allele of Akt1 is sufﬁcient to rescue
mice during embryonic development and postnatal survival.
Together with the double and triple knockout studies, there is
increasing evidence to show that each Akt isoform possesses non-
overlapping functions. In addition to differences in tissue expression,
different Akt isoforms localise to distinct subcellular compartments.
For example, Akt1 is predominantly localised to the cytoplasm and
activated at the plasmamembrane, whereas Akt2 is preferentially local-
ised to the cytosol but colocalisedwithmitochondria. In contrast, Akt3 is
localised both to the nucleus and nuclear membranes [16,17]. However,
subcellular localisation also varies between tissues. For example, Akt1 is
mainly located in the nucleus in murine peritoneal macrophages and
human THP1 cells, whereas Akt3 is located in the cytoplasm. In contrast,
Akt1 is predominantly cytosolic and Akt3 is nuclear in hepatocytes [18].
These ﬁndings strongly suggest that plasma membrane activation
processesmay not be required by all Akt isoforms, or by any one isoform
in different tissues. A further level of complexity exists based on acute vs
chronic activation of Akt. For example, acute Akt1 activation can
preserve the contractility of cardiomyocytes whereas chronic activation
leads to dilatation and hypertrophy [19]. Therefore, the functions of Akt
isoforms are tissue-speciﬁc, temporally-regulated and cell context-
dependent. Elucidation of the complex role of individual Akt isoforms
is therefore required for each tissue and cell type.
2. Role of Akt in vascular disease
Signiﬁcant advances have been made in the last two decades to
elucidate the roles of Akt isoforms in cancer, development, metabolism
and cardiovascular disease. Several excellent reviews have summarised
the molecular regulation of Akt and its downstream signalling [11,20,
21]. The important role of Akt isoforms in cardiomyocyte survival
and cardiac hypertrophy, both under physiological or pathological
conditions, has also been reviewed [19,22–25]. Here we will summarise
the consequences of Akt activation, focusing on cell survival, cellproliferation, and migration, and the role of individual isoforms in
cells whose abnormal function underlies vascular disease, including
endothelial cells (EC), vascular smooth muscle cells (VSMCs) and
macrophages. We will also review recent studies determining the role
of individual Akt isoforms in vascular disease, including atherosclerosis,
vascular remodelling and aneurysm formation.
2.1. Akt in survival signalling
Apoptotic cell death is a common feature in many physiological and
pathological processes in the cardiovascular system, including vessel
remodelling, atherosclerosis and vascular injury. However, survival
signalling pathways, especially the pleiotropic effects of Akt signalling
in cardiovascular disease, remain unclear. Critical survival signalling
pathways in the cardiovascular system whose effects are mediated
through Akt include circulating factors such as insulin-like growth
factor-1 (IGF-1) and platelet-derived growth factor (PDGF), cell–cell
and cell–extracellular matrix contact, and mechanical signals such as
stretch and shear stress from blood ﬂow. Of these, one of the most
potent anti-apoptotic growth factors is IGF-1 [26–28]. The IGF-1 recep-
tor possesses intrinsic tyrosine kinase activity and a number of down-
stream mediators have been identiﬁed, including Insulin Receptor
Substrate-1 (IRS-1), PI3-K, and mitogen-activated protein kinase
(MAPK). The canonical PI3-K comprises a regulatory p85 subunit and
a catalytic p110 subunit that directly phosphorylates the ribosomal
protein kinase p70s6k [29], the rho family polypeptide Rac [30], the
serum and glucocorticoid-induced kinases SGK [31–33], and the
serine/threonine kinase Akt [34,35] (Fig. 1). Of all these pathways,
much of the anti-apoptotic function of IGF-1 resides in Akt [36,37].
PI3K activation leads to phosphorylation of phosphoinositides (PtdIns),
including PtdIns(3,4,5)P3 and PtdIns(3,4)P2 (PIP3 and PIP2). Plasma
membrane-anchored PtdIns(3,4,5)P3 and PtdIns(3,4)P2 bind to the
PH domains of Akt and the phosphoinositide-dependent kinase-1
(PDK1). Activated PDK1 stimulates Akt activity by direct binding and
phosphorylation of Threonine 308 in the central catalytic domain [38].
Further activation of Akt is regulated through phosphorylation by the
mammalian target of rapamycin complex 2 (mTORC2) on Serine 473
in the C-terminal regulatory domain. Once activated by phosphoryla-
tion at both sites, Akt disassociates from the membrane and further
phosphorylates multiple effectors to activate pro-survival or inactivate
pro-apoptotic signalling pathways.
Akt critically regulates apoptosis in many cell types, following a
variety of stimuli, and constitutively active (CA) and dominant negative
(DN) forms of Akt can inhibit or promote apoptosis respectively [39,40].
Akt inhibits apoptosis via a variety of mechanisms (Fig. 1), including
phosphorylation of the pro-apoptotic proteins Bad and caspase 9 [41,
42]. Bad is a member of the Bcl-2 family, and promotes apoptosis by
interacting with other Bcl-2 family member proteins. Phosphorylation
of Bad sequesters this protein in an inactive form preventing this asso-
ciation [41]. In contrast, caspase 9 is a cysteine protease intimately
involved with regulating and executing apoptosis. Caspase 9 cleavage
occurs during formation of a pro-apoptotic complex, the apoptosome,
that is responsible for apoptotic signalling in response to the release of
cytochrome C from mitochondria. Akt phosphorylation of caspase 9
prevents its cleavage and activation, thus inhibiting apoptosis [42]. Akt
also phosphorylates glycogen synthase kinase 3β (GSK3β), which not
only regulates glucose metabolism, but also induces apoptosis [43].
Akt can also phosphorylate theO subclass of the forkhead family of tran-
scription factors [44–46], including FOXO1, FOXO3a, FOXO4 and FOXO6
in humans. Akt phosphorylation of FOXO3a leads to its association with
14-3-3 proteins and retention in the cytoplasm. Survival factor with-
drawal leads to FOXO3a dephosphorylation, nuclear translocation, and
activation of pro-apoptotic target genes, such as FasL, BIM, PUMA and
TRAIL [45]. In addition to inactivation of pro-apoptotic proteins, Akt
also upregulates anti-apoptotic genes such as Bcl-2, Bcl-XL [47], and
survivin [48]. Akt also activates IκB kinase-α (IKK-α), causing the
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crease the transactivation potential of the RelA/p65 subunit of NF-κB
[50]. In endothelial cells (EC), Akt1 activates endothelial nitric oxide
synthase (eNOS), which promotes cell survival by nitrosylating the re-
active cysteine residue in caspases [51,52]. Although all of these path-
ways downstream of Akt activation have been described (Fig. 1), not
all are activated or important in different cell types. For example, Akt1
prevents apoptosis in vascular smooth muscle cells (VSMCs) predomi-
nantly via the inhibition of both FOXO3a and GSK3 [53].
2.2. Akt in cell proliferation
VSMCproliferation plays an important role in atherosclerosis, vascu-
lar remodelling and neointima formation. However, the role of Akt
activation in vascular cell proliferation is unclear, in part because of dif-
ferent effects on normal cells vs. those seen in disease. For example,
although Akt is frequently observed to be activated during proliferation
and invasion in cancer cells, Akt1 phosphorylation (Ser473) is reduced
in VSMCs in human atherosclerotic plaques [53], and reduced
phospho-Akt2 levels and phospho-AKT2/total AKT ratios are seen in
the media of human aortic aneurysms [54].
Akt1 may be necessary but not sufﬁcient to promote VSMC prolifer-
ation. For example, inhibition of Akt signalling with a dominant nega-
tive Akt mutant (AA-Akt) potently inhibits VSMC proliferation, DNA
synthesis and G1/S exit, associated with increased p21 expression [55].
VSMCs from Akt1-deﬁcient mice also show impaired increase in cell
number in culture, although this study did not examine proliferationFig. 1. Akt-mediated survival signalling. IGF1R possesses intrinsic tyrosine kinase activity. Once
autophosphorylation stimulates recruitment, phosphorylation and activation of the adaptor p
PIP2 to PIP3. Plasma membrane-anchored PIP3 and PIP2 attract and bind to the PH domains o
in the central catalytic domain by PDK1 and subsequent phosphorylation of S473 in the C-term
and further phosphorylates multiple downstream effectors to promote cell survival, either th
inactivate pro-apoptotic targets such as Bad, Caspase 9, FOXOs and GSK3.vs. apoptosis [56]. In contrast, serum and insulin/IGF-1 both stimulate
Akt phosphorylation in vitro, but only serum not insulin/IGF-1 pro-
motes MAPK activation and VSMC proliferation. Furthermore, tissue
speciﬁc activation of Akt1 in endothelial cells suppresses lesion forma-
tion after carotid ligation via increased NO production, preservation of
a functional endothelial layer, and suppression of VSMC proliferation
[57]. Similarly, forced expression of Akt1 in VSMCs does not induce
VSMC proliferation in normal arteries, after carotid ligation, or in ath-
erosclerosis [58]. In addition, cell proliferation was 50% lower in
VSMCs derived from Akt2/LDLr double knockout mice than LDLr KO
mice, suggesting a role of Akt2 in VSMC proliferation, although Akt1 is
the major isoform expressed in VSMCs [59].2.3. Akt in cell migration
VSMCmigration from the media to the intima occurs in both neoin-
tima formation and vessel remodelling. Intimal VSMCs play a protective
role in plaque stabilisation, althoughmigrated synthetic VSMCs can also
secreteMMPs to degrade ECM, promoting features of plaque vulnerabil-
ity. Akt potently drives cell motility through dynamic polymerisation
and stabilisation of intracellular ﬁlaments [60,61]. Indeed, expression
of an activated Akt in ﬁbroblasts was sufﬁcient to remodel actin
ﬁlaments to promote migration, whereas disruption of Akt activity re-
versed the migratory effect [62]. Although Akt1 and Akt2 are differen-
tially required for migration by ECs, VSMCs and macrophages, the
general effect for Akt activation is to promote cell migration. However,activated by binding to ligands such as insulin/IGF1 to its extracellular domain, receptor
rotein IRS1 and which in turn activates PI3K. PI3K activation leads to phosphorylation of
f Akt and PDK1. Inactive Akt is stimulated via direct binding and phosphorylation of T308
inal regulatory domain by mTORC2. Fully activated Akt disassociates from the membrane
rough phosphorylation to activate pro-survival signalling pathways such as NF-kB or to
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nalling pathways.
Akt is a necessary and sufﬁcient mediator of VEGF-induced EC
migration, through eNOS phosphorylation-mediated NO release, phos-
pholipase C-γ (PLC-γ) activation and F-actin reorganisation [63].
Importantly, Akt1, the major isoform regulating NO release in ECs, is
also critical for vascular permeability and leukocyte migration into
inﬂamed tissues, evident by reduced neutrophil and monocyte inﬁltra-
tion in Akt1−/− but not in Akt2−/−mice [64]. Akt mediates VSMC mi-
gration, which is mainly regulated through MMP activation and ECM
degradation. For example, Akt1 mediates VSMC migration through
MMP2 secretion, Rac1-GTP activation, and dorsal rufﬂe formation [56].
Genetic deletion or siRNA knockdown of Akt1 in VSMCs drastically
reduces MMP2 expression and VSMC migration, after either serum or
PDGF [56], and the reduced migration of Akt1-null VSMCs can be
rescued by Akt1 reintroduction. In contrast, how Akt2 promotes VSMC
migration is less clear. Although migration of VSMCs from Akt2/LDLR
double knockout mice was 50% lower than control LDLR null mice,
Akt2 null VSMCs showed increased MMP expression, especially MMP2
and MMP9 [59]. VSMCs of Akt2-null mice showed increased MMP9
but reduced TIMP1 expression. In vitro Akt2 also stimulates TIMP-1
and inhibits MMP9 In human aortic VSMCs through the inhibition of
FOXO1 [54].
Migration of macrophages is tightly regulated through chemotactic
signalling downstream of Akt2 but not Akt1. Thus, adhesion, spreading
and chemokine-induced migration are similar in monocytes from
Akt1−/− and control mice [56]. In contrast, migration of Akt2−/−mac-
rophages is impaired when stimulated with monocyte chemoattractant
protein-1 (MCP-1/CCL2) or macrophage colony-stimulating factor (M-
CSF or CSF-1) [65]. Akt2−/−macrophages have reduced C-C chemokine
receptor type 2 (CCR2) expression, blunted Rac-1 activity and disrupted
F-actin structures, in comparison with Akt1-null or wt macrophages
[66].Moreover, Akt2 also plays a dominant role in promotingneutrophil
migration [67].
3. Role of different Akt isoforms in cell types comprising vascular
lesions
3.1. Akt isoforms in endothelial cells
Endothelial cells (ECs) predominantly express Akt1 [68,69] which
mediates EC survival andmigration [24,70], with important roles in pro-
cesses such as angiogenesis and regulation of vascular tone [71]. Various
stimuli such as vascular endothelial growth factor (VEGF) activate Akt
in ECs, resulting in Akt-dependent phosphorylation of endothelial nitric
oxide synthase (eNOS) to promote NO release; NO is a critical regulator
of vascular tone and blood ﬂow, and also regulates vascular remodelling
and angiogenesis. The isoform-substrate speciﬁcity for Akt1 vs. Akt2 in
EC has been examined recently using conditional knockout mouse
models of Akt1−/− and Akt2−/− in combinationwith phosphoproteomic
analysis, demonstrating that eNOS is a preferential target of Akt1[69].
Indeed, loss of Akt1 but not Akt2 in ECs inhibited retinal angiogenesis,
indicating a non-redundant function of Akt1 in angiogenesis. Further-
more, Akt1 but not Akt2 in ECs uniquely phosphorylates protein sub-
strates implicated in cardiovascular disease, including FOXOs and eNOS
[69].
3.2. Akt isoforms in vascular smooth muscle cells
Akt1 is the predominant isoform expressed in VSMCs,where amajor
role is prevention of apoptosis [6,54,56,58]. For example, Akt1 is both
necessary and sufﬁcient for the survival of cultured rat VSMCs following
oxidative stress, and dominant negative inhibition of endogenous Akt
suppresses IGF1-dependent survival in VSMCs [53,72], conﬁrming also
that Akt is a major downstream target of the IGF1/PI3K signalling
pathway. Akt1-null VSMCs show increased susceptibility to serumstarvation and stress-induced apoptosis [73], whereas expression of
constitutive active Akt1 inhibits oxidative stress-induced VSMC apopto-
sis both in vitro and in vivo, through negative regulation of FOXO3a and
GSK3. In addition, as described above, Akt1 also regulates VSMC prolif-
eration and migration, the latter due to reduced Rac-1 activity and
MMP-2 secretion [56].
3.3. Akt isoforms in macrophages
The expression and activation of Akt isoforms are more complex in
macrophages than in ECs and VSMCs. Akt1 and Akt2 are both highly
expressed to similar levels in macrophages [59,65,66], whereas Akt3
accounts for only ~25% of total Akt expression [18]. Akt regulatesmacro-
phage survival, NO synthesis, cytokine secretion and programming [74].
For example, Akt1 promotes macrophage IFN-β expression by negative
regulation of GSK3β or direct phosphorylation of β-catenin [75]. Recent
studies show that Akt1 and Akt2 differentially regulate macrophage
polarisation [76,77]. Akt1−/− but not Akt2−/− macrophages show
hyper-sensitivity to lipopolysaccharide (LPS), and AKT1−/− macro-
phages display a pro-inﬂammatory M1 phenotype, whereas Akt2−/−
macrophages show an anti-inﬂammatory M2 phenotype. In vitro, Akt1
deﬁciency has no effect on macrophage adhesion, migration or lipopro-
tein uptake, but potently suppresses oxidised low-density lipoprotein
(oxLDL)-induced macrophage apoptosis [73]. In contrast, Akt2−/−mac-
rophages have increased expression of M2 markers, reduced foam cell
formation and impaired migration [65,66]. The opposing effects of Akt1
and Akt2 in macrophage M1/M2 polarisation, inﬂammation and choles-
terol accumulation indicate that Akt isoformsmight have completely dif-
ferent or even opposing effects on atherosclerosis. Finally, as a minor
formof Akt inmacrophages, Akt3 is not involved in cell survival, but sup-
presses foam cell formation by reducing lipoprotein uptake and promot-
ing acetyl-CoA acetyltransferase-1 (ACAT-1) degradation [18].
4. Role of Akt in vascular disease
4.1. Akt isoforms in atherosclerosis
The atherosclerotic plaque comprises an accumulation of vascular
smooth muscle cells, inﬂammatory cells (macrophages, mast cells)
and immune cells (T lymphocytes, dendritic cells) with both intracellu-
lar and extracellular lipid and debris. Endothelial dysfunction and
macrophage migration are both early and constant features of athero-
sclerosis, whereas, the dynamic balance of VSMC proliferation, migra-
tion, dedifferentiation and death plays an important role in both
atherogenesis and plaque stability. For example, VSMC apoptosis direct-
ly induces multiple features of plaque vulnerability in atherosclerosis,
including ﬁbrous cap thinning, necrotic core expansion, and both local
and systemic inﬂammation [78]. Chronic low-level VSMC apoptosis
also promotes atherogenesis, calciﬁcation and medial degeneration
(cystic medial necrosis), characterised by depletion of VSMCs and
ECM degradation [79]. Macrophage apoptosis is also present in ad-
vanced plaques, promoting necrotic core formation and release of pro-
inﬂammatory cytokines [80].
Both Akt1 and Akt2 are expressed in blood vessels including the
aorta, femoral and carotid arteries. Akt1 is the predominant isoform
expressed in endothelial cells and VSMCs [6,68], whereas Akt2 ismostly
expressed in ﬁbroblasts [4]. Akt3 is barely detectable in the vasculature.
Atherosclerosis results in changes in expression and phosphorylation of
both Akt and its downstream signallingmolecules. For example, medial
VSMCs maintain Akt activity and FOXO3a phosphorylation, whereas
plaque intimal VSMCs show reduced Akt phosphorylation and in-
creased expression of active (unphosphorylated) FOXO3a [53], suggest-
ing that Akt activity and Akt-mediated VSMC survival may play a
protective role in atherogenesis.
Indeed, genetic depletion of Akt1 induces endothelial cell dysfunc-
tion, reduces VSMC migration and survival, promotes atherosclerosis
Table 1
Studies and effects of Akt isoforms in atherosclerosis in mice.
Targeted Akt isoform Phenotype/morphology Mechanism Reference
Akt1 Tg SM22αAkt1ER/ApoE−/− ↓ atherosclerosis, VSMC survival [58]
Genetic depletion Akt1−/−/ApoE−/− ↑ atherosclerosis, ↑ coronary lesions Inﬂammation, EC and macrophage apoptosis [73]
Akt2−/−/LDLR−/− ↑ insulin resistance,
↓ atherosclerosis,
VSMC survival, collagen homeostasis [59]
Akt2−/−/LDLR−/− No effect – [65,66]
Akt3−/−/ApoE−/− ↑ atherosclerosis, ↑ foam cells Foam cell formation [18]
BMT Akt1−/−→ ApoE−/− No effect – [66]
Akt1−/−→ LDLR−/− No effect – [65]
Akt2−/−→ LDLR−/− ↓ atherosclerosis Macrophage migration and polarisation [65,66]
Akt3−/−→ ApoE−/− ↑ atherosclerosis, ↑ foam cells Foam cell formation [18]
61H. Yu et al. / Vascular Pharmacology 71 (2015) 57–64and coronary artery obstruction, and induces features of plaque vulner-
ability [56,73]. The detrimental effect of Akt1 deﬁciency on atheroscle-
rosis was not reversible by reconstitution with wild-type bone
marrow [73], demonstrating that the changes are mediated by vessel
wall cells.
Akt1 not only has multiple downstream targets but also can have
distinct targets in different cells. For example, Akt1 stimulates eNOS in
endothelial cells but not in VSMCs. Chronic Akt activation may even in-
duce apoptosis, by feedback inhibition of PI3K [81]. Studies usingwhole
body Akt1 knockoutmice have therefore been supplemented by studies
using tissue-speciﬁc knockout or overexpression. For example, VSMC-
speciﬁc expression of a hydroxytamoxifen-activated Akt1 allele (Akt-
ER™) reduced VSMC apoptosis, reduced plaque formation, and in-
creased plaque collagen and VSMC content, indicating that VSMC Akt1
protects against atherosclerosis and promotes plaque stability. In addi-
tion to well-established FOXO3a targets p27, cyclin D1, bim, bcl6 and
gadd45α, the apoptosome component Apaf1 was shown to be a novel
downstream apoptosis mediator regulated by Akt/FOXO3a signalling.
In contrast, a deleterious role for Akt2 in atherosclerosis has recently
been elucidated. In vitro, loss of Akt2 impairs VSMCproliferation,migra-
tion and collagen synthesis and alters the expression of MMPs and
TIMPs. However, Akt2 deﬁciency reduced atherosclerotic plaques in
both carotid arteries and aortic roots, characterised by reduced collagen
content, enlarged necrotic core and elevated apoptosis [59], despite
Akt2−/−/LDLR−/−mice having both diabetes and increased cholesterolFig. 2.Akt isoforms in EC, VSMCandmacrophage function in atherosclerosis. ECs andVSMCspre
VSMCs, Akt1 phosphorylates FOXO3a and GSK3 to inhibit apoptosis. Akt1 plays a protective ro
potently induces inﬂammation, the M1 phenotype, foam cell formation and CCR2-mediated m
macrophage foam cell formation and is found to be anti-atherogenic.levels. Although it was suggested that increased VSMC apoptosis in the
absence of Ak2 might be responsible for the phenotype, Akt1 is the
major isoform expressed in VSMCs, and a more likely effect may be
due to loss of macrophage Akt2. (see below).
Macrophage Akt1 and Akt2 also have different effects on atheroscle-
rosis. Transplantation of foetal liver cells from Akt1 or Akt2 deﬁcient
mice to LDLR−/− mice showed that Akt2−/− → LDLR−/− but not
Akt1−/−→ LDLR−/− or WT−/−→ LDLR−/− dramatically reduced early
atherosclerotic lesion formation, and also suppressed advanced athero-
sclerotic lesions [65]. Bonemarrow transplantation (BMT) studies dem-
onstrated a very similar protective role of macrophage Akt2 deﬁciency
in atherosclerosis progression [66]. In both studies, in vitro data sup-
ported a role for Akt2 in macrophage migration, inﬂammation and
polarisation, suggesting that Akt2 deﬁciency reduces atherosclerosis
through impaired macrophage function.
Finally, although predominantly expressed in brain, Akt3 also has
a protective role in atherosclerosis [18]. Genetic ablation of Akt3 in
ApoE−/− mice led to a 2-fold increase in atherosclerotic lesions,
and bone marrow transplantation of Akt3−/−/ApoE−/− to ApoE−/−
mice also resulted in a signiﬁcant increase of atherosclerosis [18].
Akt3 deﬁciency did not affect macrophage apoptosis, but promoted
macrophage cholesterol accumulation, lipoprotein uptake and foam
cell formation in vitro, via stabilising Acetyl-Coenzyme A acetyl-
transferase 1 (ACAT1). The ﬁndings of transgenic, genetic deletion
and tissue-speciﬁc deletion studies for individual Akt isoforms indominantly express Akt1. In ECs, Akt1 activates eNOS andNF-κB to promote cell survival. In
le in EC and VSMC survival to inhibit atherosclerosis. In macrophages, Akt2 but not Akt1
igration, aggravating atherosclerosis. As a minor isoform in macrophages, Akt3 inhibits
62 H. Yu et al. / Vascular Pharmacology 71 (2015) 57–64atherosclerosis are summarised in Table 1, and the role of Akt iso-
forms in different cell types and their effects on atherosclerosis are
shown in Fig. 2.
4.2. Akt isoforms in vascular remodelling
Vascular remodelling occurs both physiologically and pathologically
in response to changes in ﬂow. Thus, ﬂow reduction results in remodel-
ling leading to reduced lumen size and vessel wall thickness, and vice
versa. Remodelling is regulated by Akt in both ECs and VSMCs, particu-
larly Akt1. For example, expression of an endothelial cell-speciﬁc consti-
tutively active Akt1 transgene signiﬁcantly attenuated neointima
formation in carotid arteries after ligation [57], mediated through inhi-
bition of neointimal cell apoptosis and Akt1-mediated eNOS activation
in ECs. Similarly, although Akt1 activation in VSMCs does not promote
proliferation in vivo or induce neointimal formation, it potently
inhibitedmedial VSMC apoptosis and negative remodelling after carotid
ligation [58]. Consistent with these studies, Akt1-deﬁcient mice show a
2-fold increase in neointima formation compared with Akt1+/+ mice,
and Akt1 also modulates phenotypic conversion of VSMCs, highlighting
a protective role of Akt1 in vascular remodelling [82].
4.3. Akt isoforms in aneurysm formation
Aortic aneurysms are characterised by N1.5 fold increase in diameter
of the aorta, and both the thoracic aorta (TAA) or abdominal aorta
(AAA) can be affected [83]. The aneurysm is characterised bymedial de-
generation, loss of VSMCs, VSMC apoptosis, activation of matrix metal-
loproteinases (MMPs) and inﬂammation [84–86].
Akt isoforms are implicated in aneurysm formation, although
there is a degree of controversy in the literature. For example, Akt2
appears to have a protective role in aortic aneurysm formation and
dissection [54]. Akt2 but not Akt1 levels were signiﬁcantly reduced
in the whole aortic wall of human TAAs, and phospho-Akt473 levels
and phospho-Akt/total Akt ratios were signiﬁcantly reduced in TAA
versus control tissues, indicating reduced activation of Akt. Although
Akt2−/−mice did not develop dissection spontaneously, Angiotensin
II challenge led to aortic aneurysms, with signiﬁcant increase in the
diameter of aortic segments, lesions and ruptures in Akt2−/− vs. con-
trol mice. Severe elastic ﬁbre disruption was observed followed by
increased apoptosis and inﬂammatory cell inﬁltration in the vessel
wall of Angiotensin II-infused Akt2−/− mice. Furthermore, expres-
sion of MMP9 was increased whereas TIMP1 was decreased in lesion
segments in these animals. Further experiments suggest that Akt2
inhibits MMP-9 and stimulates TIMP-1 expression by preventing
FOXO1-mediated MMP-9 transcription and GATA1-regulated TIMP-
1 transcription [54].
The role of Akt in AAA development was examined using an
elastase-treated mouse model [87]. Elastase-perfused aortas showed
increased phosphorylation of Akt308, but not Akt473 in male mice,
which correlated with increased AAA formation. Interestingly, this
study reported consistently elevated Akt activity both in human
and mouse AAA. These differing ﬁndings may be due to different an-
imal models and human tissue sites, and also the effect of isoform
compensation, where knockout of one isoform may result in com-
pensatory increases in other isoforms. Importantly, treatment with
a broad-spectrum Akt inhibitor signiﬁcantly reduced Akt phosphor-
ylation, but only resulted in a small reduction in AAA development,
suggesting that phosphorylation of Akt is involved in AAA initiation,
but is not critical for AAA progression.
5. Conclusions and future perspectives
Signiﬁcant progress has been made towards understanding the
precise roles of individual Akt isoforms in vascular disease, including
atherosclerosis, vascular remodelling and aneurysm formation. Basedon ﬁndings from tissue-speciﬁc transgenic or knockout animal models,
Akt1 is the predominant isoform expressed in the vasculature including
EC and VSMCs. Akt1 activation potently mediates cell survival and pro-
tects against atherogenesis and negative vessel remodelling. Akt3, a
minor isoform of total Akt, may also have similar anti-atherogenic ac-
tions to Akt1. In contrast, Akt2 is detrimental in atherosclerosis, through
aberrant macrophage migration, inﬂammation, polarisation, lipid
uptake, and foamcell formation. Thus, Akt1 andAkt2 are not only differ-
entially expressed in the vasculature but also have distinct and even op-
posite functions in vascular disease. Bearing in mind the weak
expression of Akt2 in ECs and VSMCs, the protective role conferred by
Akt2 in aneurysm formation and dissection needs to be further
validated.
The current studies also leave many unanswered questions. For
example, do the current animal ﬁndings correlate with human tissues,
and what is the clinical signiﬁcance of altered Akt activity in human
disease? What level of Akt activation leads to distinct and non-
compensated actions achieved by individual Akt isoforms? How do we
account for the apparent disparate roles of Akt2 in diabetes and athero-
sclerosis, when atherosclerosis is the major cause of death in diabetes?
Are Akt or isoforms of Akt therapeutic targets considering the wide
tissue distribution and fundamental role in multiple processes? The
last decade has clariﬁed the role of individual isoforms in animal tissues;
the next decade should clarify their relevance to human vascular
disease.
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